NDA 220295 · Intercept
Lynavoy
Linerixibat · Oral · Ileal Bile Acid Transporter Inhibitor
NovelOrphanCDER novel approval, Mar 17, 2026: To treat cholestatic pruritus associated with primary biliary cholangitis
Last checked: Nov 20, 2026Latest source record: Mar 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Mar 17, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
9
3 Phase 3, 0 recruiting
FAERS reports
57
3 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 29, 2026.
LYNAVOY is indicated for the treatment of cholestatic pruritus associated with primary biliary cholangitis (PBC) in adult patients. Limitations of Use Avoid use of LYNAVOY in patients with decompensated cirrhosis or those with prior or active hepatic decompensation events (e.g. variceal hemorrhage, ascites, hepatic encephalopathy) [see Use in Specific Populations (8.7) , Clinical Pharmacology (12.3) ] . LYNAVOY is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of cholestatic pruritus associated with primary biliary cholangitis (PBC) in adult patients. ( 1 ) Limitations of Use Avoid use of LYNAVOY in patients with decompensated cirrhosis or those with prior or active hepatic decompensation events (e.g. variceal hemorrhage, ascites, hepatic encephalopathy). ( 1 )
Mechanism: Linerixibat is a reversible inhibitor of the ileal bile acid transporter (IBAT). It decreases the reabsorption of bile acids in the terminal ileum leading to their increased fecal elimination. Cholestatic pruritus is a common symptom in patients with PBC, and the pathophysiology of pruritus in patients with PBC is not completely understood. Although the complete mechanism by which linerixibat improves pruritus in PBC patients is unknown, it may involve inhibition of the IBAT as observed by a decrease in mediators of pruritus including serum bile acids [see Clinical Pharmacology (12.2) ] .
Therapeutic areas: Gastroenterology and liver
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- LYNAVOY · LINERIXIBAT 40MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Linerixibat" as an intervention, any sponsor and status, largest first.
- Linerixibat Long-term Safety, and Tolerability StudyPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04167358 · 242 participants · Start Jul 8, 2020 · Primary completion Sep 30, 2026
Drug: Linerixibat · For: Cholestasis
Sites: Sacramento, California; West Hollywood, California; Miami, Florida · 94 sites in all
- Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04950127 · 238 participants · Start Aug 27, 2021 · Primary completion Oct 28, 2024
Drug: Linerixibat; Placebo · For: Pruritus
Sites: Erlangen, Germany; Münster, Germany; Cambridge, United Kingdom · 5 sites in all
- Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary CholangitisPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02966834 · 147 participants · Start Jan 11, 2017 · Primary completion Apr 15, 2020
Drug: Placebo; GSK2330672 · For: Cholestasis
Sites: Phoenix, Arizona; Sacramento, California; Miami, Florida · 66 sites in all
GlaxoSmithKlineGSK (GSK)
NCT05133830 · 52 participants · Start Nov 23, 2021 · Primary completion May 31, 2022
Drug: Obeticholic acid; Linerixibat · For: Pruritus
Sites: Baltimore, Maryland
- J-LINX: Japan LINerixibat eXtension StudyPivotal-lookingNot yet recruiting
GlaxoSmithKlineGSK (GSK)
NCT07860710 · 40 participants (planned) · Start Oct 9, 2026 · Primary completion Oct 23, 2028
Drug: Linerixibat · For: Pruritus
GlaxoSmithKlineGSK (GSK)
NCT05435170 · 23 participants · Start Aug 11, 2022 · Primary completion Oct 10, 2022
Drug: linerixibat · For: Pruritus
Sites: Cambridge, United Kingdom
GlaxoSmithKlineGSK (GSK)
NCT04053023 · 19 participants · Start Aug 27, 2019 · Primary completion Nov 25, 2019
Drug: GSK2330672 (linerixibat); Obeticholic acid · For: Cholestasis
Sites: Cambridge, United Kingdom
- Phase I Study of Linerixibat in Adults With Moderate Hepatic Impairment and Healthy ControlsCompleted
GlaxoSmithKlineGSK (GSK)
NCT05393076 · 8 participants · Start Jul 19, 2022 · Primary completion Dec 6, 2022
Drug: Linerixibat · For: Pruritus
Sites: Orlando, Florida; San Antonio, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use25
- diarrhoea14
- drug interaction11
- drug ineffective9
- abdominal pain upper6
- nausea4
- product dose omission issue3
- pruritus3
- abdominal discomfort2
- constipation2
- intentional product misuse2
- therapeutic product effect incomplete2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2026 | 57 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus.
Levy C, Kendrick S, Bowlus CL, et al. · Clin Gastroenterol Hepatol 2023 · Randomized Controlled Trial, Multicenter Study
- Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Hirschfield GM, Bowlus CL, Jones DEJ, et al. · Lancet Gastroenterol Hepatol 2026 · Randomized Controlled Trial, Multicenter Study
- Pharmacological Therapy of Pruritus in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Medina-Morales E, Barba Bernal R, Gerger H, et al. · J Clin Gastroenterol 2023 · Systematic Review, Meta-Analysis
- Serum bile acid change correlates with improvement in pruritus in patients with primary biliary cholangitis receiving linerixibat.
Karatza E, Swift B, Carreño F, et al. · Liver Int 2024 · Clinical Trial, Phase II, Randomized Controlled Trial
- Pharmacokinetics and ADME Characterization of Intravenous and Oral [14C]-Linerixibat in Healthy Male Volunteers.
Zamek-Gliszczynski MJ, Kenworthy D, Bershas DA, et al. · Drug Metab Dispos 2021 · Clinical Trial, Research Support, Non-U.S. Gov't
- Population Dose-Response-Time Analysis of Itch Reduction and Patient-Reported Tolerability Supports Phase III Dose Selection for Linerixibat.
Carreño F, Karatza E, Mehta R, et al. · Clin Pharmacol Ther 2024 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Intercept
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.